Department of Bacteria, Parasites & Fungi, Infectious Disease Preparedness, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
Department of Bacteria, Parasites & Fungi, Infectious Disease Preparedness, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
Int J Antimicrob Agents. 2020 Jul;56(1):106041. doi: 10.1016/j.ijantimicag.2020.106041. Epub 2020 May 30.
The aim of this study was to investigate recurrent infections in individual patients caused by extended-spectrum β-lactamase and plasmid AmpC β-lactamase-producing Escherichia coli (ESBL/pAmpC-Ec) isolates with >12-month interval. The Danish national collection of ESBL/pAmpC-Ec isolates collected from January 2014 through June 2017 was screened for patients with multiple isolates with >12 months between the episodes. Isolates underwent whole-genome sequencing and were analysed for antimicrobial resistance genes, virulence genes and multilocus sequence typing (MLST). Isolates were subtyped by core genome MLST (cgMLST) and CH typing. From a total of 970 patients, 15 unrelated patients experienced recurrent infections with ESBL/pAmpC-Ec. Of the 15 patients, 10 (67%) were found to be infected a second or third time with a genetically identical or similar strain. The resistance and virulence properties of the strains were similar in individual patients, however they were quite diverse when comparing between patients. Recurrent ESBL/pAmpC-Ec bloodstream infections of genetically related strains occurring with >12-month interval might be related to the previous episode and to a lesser extent be caused by re-infection. With >1000 days between the first and second episode of genetically similar strains (four allele differences), the recurrent infection is likely due to long-term host colonisation by ESBL/pAmpC-Ec. From this analysis, strains able to cause such recurrent infection were relatively diverse between patients. Knowledge about host and strain factors influencing such recurrent infections is needed to implement preventive measures.
本研究旨在调查间隔>12 个月的产超广谱β-内酰胺酶和质粒型 AmpCβ-内酰胺酶大肠埃希菌(ESBL/pAmpC-Ec)分离株引起的个别患者的反复感染。对 2014 年 1 月至 2017 年 6 月期间丹麦国家收集的 ESBL/pAmpC-Ec 分离株进行了筛选,以寻找>12 个月两次发作的患者。对分离株进行全基因组测序,并分析其抗菌药物耐药基因、毒力基因和多位点序列分型(MLST)。通过核心基因组 MLST(cgMLST)和 CH 分型对分离株进行亚型分析。从 970 名患者中,15 名无关联的患者经历了 ESBL/pAmpC-Ec 的反复感染。在这 15 名患者中,有 10 名(67%)患者被发现第二次或第三次感染了遗传上相同或相似的菌株。尽管在个别患者中,菌株的耐药性和毒力特性相似,但在患者之间却存在很大差异。间隔>12 个月发生遗传相关的 ESBL/pAmpC-Ec 血流感染的反复感染可能与先前的感染有关,而与再感染的关系较小。第一次和第二次感染遗传相似的菌株之间间隔>1000 天(4 个等位基因差异),这种复发性感染很可能是由于 ESBL/pAmpC-Ec 长期定植于宿主。通过本分析,发现患者之间引起这种反复感染的菌株相对多样化。需要了解影响这种反复感染的宿主和菌株因素的知识,以实施预防措施。